A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level.
Pfeifer R, Henze J, Wittich K, Gosselink A, Kinkhabwala A, Gremse F, Bleilevens C, Bigott K, Jungblut M, Hardt O, Alves F, Al Rawashdeh W.
Pfeifer R, et al.
Theranostics. 2022 Jun 13;12(11):4834-4850. doi: 10.7150/thno.68966. eCollection 2022.
Theranostics. 2022.
PMID: 35836798
Free PMC article.
Therapeutic T cells were genetically modified to co-express the CAR of interest and the luciferase CBR2opt. IL-2 was administered s.c. under the xenograft tumor on days 1, 3, 5 and 7 post-therapy-initiation at a dose of 25,000 IU/mouse. ...
Therapeutic T cells were genetically modified to co-express the CAR of interest and the luciferase CBR2opt. IL-2 was administered s.c …